anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To obtain a cosmetic or dermal composition of a soft paste-form, applied for makeup or treatment by using an applicator by formulating a specific amount of a wax therewith under a specified condition. CONSTITUTION: This cosmetic or dermal composition contains 12-60 wt.% at least one kind of wax having &gt;=55 deg.C, preferably 55-110 deg.C melting point in a fat phase based on the total composition. Further the composition has 3-30 Pa.s viscosity coefficient at 25 deg.C measured by a CONTRAVES-TV rotor-type viscometer having a MS-r4 moving member at 60 Hz frequency. The wax is exemplified by a beeswax, a carnauba wax, a Japan tallow, a paraffin wax and polyethylene wax. The composition is prepared by formulating a lipid component (e.g. jojoba oil and a liquid petroleum), a coloring agent, a filler, etc., kneading and cooling the formulated materials.
Process for permanent deformation of hair comprises: (i) mixing (a) a powder composition comprising at least one keratin-reducing agent which is solid or is adsorbed on a solid with (b) an aqueous liquid composition not containing a keratin-reducing agent; (ii) applying the mixture to the hair before, during or after an optional step of putting the hair under tension; (iii) allowing time for disulphide bonds in the hair to be reduced; (iv) applying a fixing composition containing at least one oxidising agent; (v) allowing time for permanent deformation; and (vi) rinsing the hair. Also claimed is a product comprising components (a) and (b) as above. Preferably the solid keratin-reducing agent is a sulphite or thiol, especially cysteine or cysteamine. The keratin-reducing agent adsorbed on a solid is thioglycolic or thiolactic acid adsorbed on a particulate solid selected from silica, clays, carbohydrates and organic polymers. The powder composition can also contain a thickener selected from guar gum, Tara gum and picea flour &#34;farine d&#39;epicea&#34;. The powder composition can also contain powdered polymers, alkaline and/or acids. The mixture contains 1-25 wt.% reducing agent. The mixture comprises 1-80 wt.% of the powder composition and 20-99 wt.% of the liquid composition. The mixture can also contain up to 30 wt.% surfactant. The mixture can also contain silicones, waxes, polymers, penetrants, swelling agents, (di)alkylene glycol ethers, alkanediols, fatty acids, lanolin derivatives, ceramides, active ingredients, hair loss inhibitors, antidandruff agents, suspension aids, sequestrants, opacifiers, dues, solar filters, perfumes etc..
The invention provides a system (100) a method (400) for Functional Neurosciences, Neuro modulation with advanced neurorehabilitation to assess, prognosticate and track nervous system recovery. The method (400) includes storing clinical data in a memory (203). The method (400) may further include training a Machine Learning (ML) model using the stored clinical data. The method (400) may further includes receiving a user input from one or more users. The method (400) may further includes determining a disease and stages of the disease using the trained AI &amp; ML model. The method (400) may further includes suggesting (410) a treatment plan based on the determined disease and the trained machine learning model. Further, the method (400) includes outputting the suggested treatment plan via a user interface.
PURPOSE:To provide a base for external drug, capable of raising the concentration of the drug component in the blood rapidly to the required level and keeping the concentration for a long period, and having stable shape, by combining a polyacrylic acid with a specific polyethylene glycol and using the mixture as a non-aqueous system. CONSTITUTION:An non-aqueous base for external drug, obtained by combining a polyacrylic acid with a polyethylene glycol having a molecular weight of &gt;=200. The time necessary to raise the drug concentration in the blood to the peak can be controlled freely by adjusting the molecular weight of the polyethylene glycol to be added to the composition. The concentration of a drug (e.g. anti-inflammatory, analgesic, antipruritic, antidermatorycotic agents) can be raised within a short time, and maintained at the level for a long period. It is a transparent glossy gel stable to the temperature change. It has extremely low interaction with drugs, and can be used as an external drug by combining with various drugs.
PURPOSE: A composition containing osmotin for preventing and treating neural diseases is provided to suppress apoptosis of nerve cells and to protect nerve cells from external stimulation and toxicity. CONSTITUTION: A composition for preventing and treating neural diseases contains osmotin. The neural diseases are Alzheimer&#39;s disease, Parkinson&#39;s disease, HIV dementia, epilepsy, stroke, manic-depressive insanity, autism, or multiple sclerosis. Osmotin is administered in 2-6 ug/ml. The composition additionally contains pharmaceutically acceptable carrier. A health food composition for preventing and treating neural disease contains osmotin.
This discloses the content and relates to an electronic equipment to relate to healthy polymerizer. This discloses the content and relates to polymerization and the healthy data of sharing. Can be by subscriber equipment from the outside or inside any number&#39;s of subscriber equipment sensor, type the user of healthy data or receive healthy data from other users or entity from manual. Subscriber equipment can save healthy data on subscriber equipment safely and the healthy data of storage on the remote data storehouse are treated in the transmission. The user of equipment can share the healthy data of the part or whole of healthy data with good friend, relative, nursing staff, medical services provider etc. Subscriber equipment can further show user&#39;s healthy data in the polymerization view of different kinds of healthy data. If received mandate, the healthy data that then also can look over other users from other users.
PURPOSE:To efficiently remove endotoxin in water during precision filtering by depositing a polymer compd. consisting of structural units expressed by specified formula and methyl methacrylate units on at least one part of the surface of a porous membrane. CONSTITUTION:This porous membrane to remove endotoxin is obtd. by depositing a polymer compd. consisting of structural units expressed by formula and methyl methacrylate units on at least one part of the surface of a porous membrane. In formula, (n) is an integer 1-20, X&lt;-&gt; is F&lt;-&gt;, Cl&lt;-&gt;, Br&lt;-&gt; or I&lt;-&gt;, Y&lt;+&gt; is a cation of quaternary ammonium salt centering around nitrogen atom. The nitrogen atom is bonded with aliphatic or aromatic residues which form a straight chain or ring. Thereby, interaction between endotoxin and the quaternary ammonium ion on the porous membrane is caused and endotoxin is adsorbed to the membrane surface by the electrostatic interaction of the membrane and endotoxin which gives electrically negative polarity.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide BAFF-R for therapeutic use capable of being clearly characterized and having a glycosylation pattern avoiding aggregation in eucaryocytes with maintaining specificity and affinity to BAFF.  &lt;P&gt;SOLUTION: A BAFF-R glycoprotein which is a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain resulting in an altered O-linked glycosylation pattern is provided. Methods and pharmaceutical compositions for treating disorders mediated with B-cells and T-cells are also provided. Ligands of TNF family, receptors and antagonists thereof and agonists, and use thereof for regulating immune responses are also provided. Partially, those depend on discovery and characterization of glycosylation patterns of human BAFF-R and variants thereof.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present invention relates to a Chinese medicine for preventing and curing cholera. It is made up by using the Chinese medicinal materials of evodia fruit, katsumada&#39;s galangal seed, turmeric, galangal root and licorice according to a certain mixing ratio. It can be made into powder or pill preparation. As compared with existent technology, it possesses the advantages of quickly-obtaining obvious therapeutic effect, convenient administration, and low cost, etc. Besides, it also possesses the functions of resolving toxin, dispersing food and transforming stagnation, dissipating cold, stopping pain, downbearing counterflow and checking vomiting, etc. and can be used for curing the diseases of coliinfection, liquor, fish and meat poisoning, vomiting and diarrhea and dyspepsia, etc.
Therapeutic bath salts for the relaxation of muscles, elimination or reduction of muscle spasms, and for the overall enhancement of a person&#39;s mood. The bath salts of the present invention are used as aromatherapy that has both the convenience of a bath and the internal mechanisms of ingested medication. The formula for the composition of the present invention includes a selected amount of magnesium sulfate trihydrate (a hydrated version of epsom salts), lithium chloride, copper gluconate, and essential oils. The oils include rosewood oil, ylang ylang oil, lavender oil and patchouli oil. The oils are provided as scents for use in the prescribed aromatherapy. The user mixes a preselected amount of the crystallized salt or liquid form of the present invention with the bath water. A period of time is allowed to elapse before the user departs the bath. By resting in the tub, the user accrues the combined benefits of external therapy and internal therapy.
The present invention relates to a TFF smart diet management system for automatically and smartly generating diet programs when a user without diet knowledge simply inputs basic information and a diet purpose. In the past, many people followed a diet thoughtlessly on the Internet without any knowledge of dieting. People performed dieting without considering environment and time to waste time unnecessarily. In a fitness-related business, diet programs vary according to individual differences of a leader and a lot of cases stopping diet due to a wrong diet program occur. According to the present invention, when a user enters the user&#39;s personal information, a diet program suitable for the user is generated. Since a diet program fit to the user without knowledge about dieting is generated, the user can perform diet effectively. More specifically, when the user inputs the user&#39;s gender, height, daily activity time, diet time, diet, occupation, and the like, a diet program based on a basal metabolic rate is generated, and thus the user can perform diet fit to the user. In other words, the diet program is differently generated with only personal information, weight and height, job, daily activity amount, diet purpose, or current weight and target weight.
PROBLEM TO BE SOLVED: To obtain a new stable and long-time acting salt of 2-oxyindole-1- carboxamide compound useful for curing pains and inflammations of articular diseases. SOLUTION: This stable and long-time acting salt of a carboxamide for curing articular diseases is a salt selected from the group consisting of salts of magnesium, calcium, benzathine and lidocaine of a compound expressed by the formula (X is H, F, Cl, an alkyl, etc.; Y is H, F, an alkyl, a cycloalkyl, etc., X and Y forms 4,5-methyldioxy, etc.; R&lt;1&gt; is an alkyl, a cycloalkyl, a phenyl, etc.), e.g. a benzathine salt of (z)-5-chloro-2,3-dihydro-3-(hydroxy-2- thienylmethylene)-2-oxo-1-H-indole-1-carboxamide(tenidap). The compound of formula I, e.g. the compound of the above example, is obtained by agitating tenidap in isopropyl alcohol, heating the obtained yellow slurry and adding an isopropyl alcohol solution of benzathine to the slurry.
A system and method are provided for simulating a Laser Induced Optical Breakdown (LIOB) protocol to establish a surgical LIOB treatment for a patient. In the system, a library of finite element models characterizing various visual defects in corneas are programmed into a computer. Further, a library of nomograms indicating specific LIOB protocols for correcting respective visual defects are programmed into the computer. As a result, a model and a corresponding nomogram may be selected in view of a patient&#39;s diagnostic information. Further, the selected model may be individualized with the diagnostic information to more precisely characterize the patient&#39;s visual defects. Thereafter, the computer simulates the indicated LIOB protocol on the individualized model in order to achieve a desired corneal configuration. When the desired corneal configuration is achieved, the final treatment plan may be determined.
1346494 Foot and mouth disease vaccines LABORATOIRE ROGER BELLON 6 May 1971 [6 May 1970] 13428/71 Heading ASB An aqueous suspension of particles of foot and mouth disease virus is prepared by culturing the foot and mouth disease virus in a cellular or tissue culture in a closed vessel at 35‹ to 40‹C. with oxygenation and agitation, and collecting in a sealed circuit an aqueous suspension of the virus particles liberated spontaneously into the culture medium from the cellular or tissue culture, all the operations being carried out without grinding the cells or cellular debris of the cellular culture or exposing the culture to the atmosphere. The viral suspension may be collected after 8-15 hours&#39; culture and may contain only the virus particles liberated from the cells without any intracellular or bound inter-cellular virus particles, after which the culture conditions may be modified by increasing the rate of agitation and reducing the temperature and degree of oxygenation (preferably the temperature is reduced to 20-25‹C and the rate of oxygenation is reduced by at least one third) so as to release the intra-cellular and bound intercellular virus particles, and the viral suspension so produced is collected preferably in one or more stages, lasting 4 to 10 hours, the suspension of released viral particles being collected after each stage. The naturally occurring virus cultured is adapted to cell culture by 3 to 5 sub-cultures, and at each sub-culture only the virus particles liberated from the cells are collected without any intra-cellular or bound intercellular virus particles. All the apparatus and pipelines connecting them are sterilisable. Foot-and-mouth disease vaccine is produced by inactivation of the aqueous suspension of foot and mouth disease virus particles to which immunity adjuvants may be subsequently added.
The invention provides a preparation method and a product of a multifunctional intestinal diagnosis and treatment preparation, wherein the multifunctional intestinal diagnosis and treatment preparation product simultaneously has a multifunctional probe for PET imaging, ultrasonic imaging and photothermal treatment, can simultaneously meet the requirements of accurate tumor positioning and high-sensitivity long-period imaging, and improves the targeting imaging efficiency of the probe on tumors. Macrophages are used as drug carriers &#34;reservoirs&#34;. The carrier is enhanced to be enriched at the tumor part through the macrophage transportation function, and the chitosan can be effectively adsorbed on the surface of intestinal mucosa.  18  The F-type nuclide is used as an imaging agent of PET. The tumor position and the metastasis are determined through PET imaging, so that the accurate positioning of the whole body tumor is realized. Fluorocarbons are used as ultrasound contrast agents. By ultrasonic imaging, the diagnostic ability of local tumors is improved. The gold nanorods have a photo-thermal effect and have the effect of treating tumor parts.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic excellent in ageing stability and UV- absorbing effect without requiring the application of a special processing treatment to a container by compounding a cinnamic acid-based UV absorber and a benzophenone-based UV absorber in specific amounts or more, respectively. SOLUTION: This ultraviolet-absorbing skin cosmetic contains (A) a cinnamic acid-based UV absorber and (B) a benzophenone-based UV absorber in an A:B ratio of 20:&gt;=1. The component A is preferably compounded in an amount of 0.01-20wt.%, and the component B is also preferably compounded in an amount of 0.01-20wt.%. The component A is preferably octyl methoxycinnamate or di-p-methoxycinnamic acid-2-ethylhexanoic acid glyceryl ester. The component B is especially preferably 2-hydroxy-4methoxy-benzophenone. The cosmetic does not cause discoloration due to light and the deterioration of smell, even when an UV absorber is not coated on the surface of a container. A container substantially having light transmission in a wavelength region of &lt;=380nm is preferably used.
1,170,741. Pelleting fusible materials. ELLIOTT ASSOCIATED DEVELOPMENTS Ltd. 14 Nov., 1966 [12 Aug., 1965], No. 34605/65. Heading B5A. Resins, e.g. cumarone, waxes, pitch, low temperature metal alloys or sulphur, are pelletized or pastillated by the discharge of molten drops thereof from a plurality of groups of spaced drop forming heads 15, each comprising a nozzle with a reciprocating plunger therein, into an elongated tank 12 of water or other cooling liquid under the liquid surface, whereof operates a slow moving stainless steel conveyer band or screw conveyer on to which the solidified drops collect and are conveyed and discharged into a sump 18 whence they are delivered, through a valve 9, to a rotary screen 20 by a pump 21 provided with a rubber or rubber lined screw impeller. Pellets that do not sink are collected against baffles 22 at the discharge end of the tank 12 and may be treated with an additive to make them sink. The tank water preferably contains an anti-stick additive e.g. a dimethyl silicone fluid, so that pellets may pile up upon one another on the conveyer without sticking. The cooling water temperature is maintained constant by continuously introducing cool water near the bottom of the tank 12 and removing overflow hotter water from the top thereof. The feed temperature to the nozzles is maintained close to the feed melting point so that the formation of &#34; tails &#34; is avoided on the drops, or the feed, e.g. sulphur, may be supercooled.
PURPOSE: A pharmaceutical composition containing Paeonia lactiflora seed extract, fraction thereof, or compound isolated from the same is provided to suppress BACE-1 activity and to treat and prevent neurodegenerative diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating neurodegenerative diseases contains Paeonia lactiflora seed extract as an active ingredient. The neurodegenerative diseases include Alzheimer&#39;s dieses, Parkinsons&#39;s disease, progressive supranuclear palsy. The extract is prepared using water, alcohol of C1-C4, or mixture solvent thereof. The pharmaceutical composition contains Paeonia lactiflora seed fraction as an active ingredient. The pharmaceutical composition also contains compounds as an active ingredient. The method for preparing the compounds comprises: a step of adding water, C1-C3 alcohol, or mixture thereof to the Paeonia lactiflora seeds to prepare Paeonia lactiflora seed extract; a step of fractioning the extract with water, dichloromethane, and ethyl acetate to prepare a fraction; a step of performing silicagel column chromatography of the fraction.
A method for producing a retrievable hairstyling using shape memory polymers is described. Here a composition is applied to the hair, said composition containing a shape memory polymer P or a macromer M that can be cross-linked to a shape memory polymer, the hair is arranged into a given (permanent) shape and said permanent shape is then fixed by means of chemical cross-linking of the macromer M under the formation of a shape memory polymer and/or under physical cross-linking of the polymer P. The polymer P and the macromer M are formed from block copolymers, each of which comprises at least a first block and at least two additional blocks. The first block is a polyol and is selected from polyethers, dimerdiol and derivatives derived therefrom, as well as from polyesters of dicarboxylic acids with diols. The additional blocks are polyesters of hydroxycarboxylic acids or their lactones. The macromer M possesses cross-linkable regions, as well as thermoplastic regions that are not cross-linkable and, after cross-linking, has a transition temperature of T&lt;SUB&gt;trans&lt;/SUB&gt;. The polymer P has a hard segment with a first transition temperature T&#39;&lt;SUB&gt;trans&lt;/SUB&gt;, which is above room temperature, and a soft segment with a second transition temperature T&lt;SUB&gt;trans &lt;/SUB&gt;which is lower than T&#39;&lt;SUB&gt;trans&lt;/SUB&gt;.
The present invention relates to a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding at least one of (i) a tumor antigen, (ii) a fragment of a tumor antigen, and (iii) a variant of (i) or (ii). The present invention further relates to a polynucleotide encoding said recombinant virus of the family Paramyxoviridae and to a host cell comprising said recombinant virus of the family Paramyxoviridae and/or said polynucleotide encoding said recombinant virus of the family Paramyxoviridae. More over, the present invention relates to a method for activating immune cells with antitumor activity in a sample comprising cancer cells and to further means, methods, and uses related to the present invention. cm 0 e- Ua -jE E E)V rC. C4 (0 .0 CL. r- L. IC (0 ~ m 0. 4- 0 LL _ o&gt; o 0~ x &lt; Z (Iw~njo) Z0IR )POOW 01 OAlleIOJ Apliqe*A 1100
A composition comprising poly(amidoamine) (PAMAM) hydroxyl- terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (&#34;BBB&#34;) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.
The application is an invention patient divisional application which is applied on January 11, 2011 with the application number 201110004638.9 and is named &#39;a compound medicinal composition for improving the oral bioavailability of paclitaxel and an application thereof&#39;. The invention discloses a compound medicinal composition for improving the oral bioavailability of paclitaxel and an application thereof. The invention further discloses a medicinal composition containing the compound medicinal composition and a paclitaxel monomer compound. The compound medicinal compound disclosed by the invention can be used for improving the oral bioavailability of the paclitaxel, and can contribute to enhancing the antic-cancer effect of the paclitaxel when used for preparing an anti-cancer medicament. In the compound medicinal composition, the paclitaxel is taken as a main anti-cancer component, and the Chinese medicine-extracted monomer compound is used for restraining the first pass effect of the paclitaxel, so that the oral bioavailability and anti-cancer effect of the paclitaxel are improved. As proved by experimental research, the compound medicinal composition is prepared into an oral medicament, and the blood concentration and anti-cancer effect of orally-taken paclitaxel can be improved.